SCHEMBL30453914

SCHEMBL30453914

Cc1cc(=O)oc2cc(NC(=O)[C@H](CCCCNC(=O)C(F)(F)F)NC(=O)OC(C)(C)C)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.58
CA9 Q16790 4/20 0.58
CA12 O43570 3/20 0.58
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 4/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HSD17B10 Q99714 2/20 0.47
SIRT5 Q9NXA8 1/20 0.47
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
CA2 P00918 1/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29396685 1.00 CA1 (0.58) CA1CA9CA12KDM4EALDH1A1
SCHEMBL13853068 0.94 CA1 (0.48) CA1CA9CA12KDM4EALDH1A1
SCHEMBL29550379 0.91 CA1 (0.61) CA1CA9CA12KDM4EALDH1A1
SCHEMBL3204645 0.91 CA1 (0.61) CA1CA9CA12KDM4EALDH1A1
SCHEMBL3098313 0.90 KDM4E (0.49) CA1CA9CA12KDM4EALDH1A1
SCHEMBL16383357 0.89 CA1 (0.63) CA1CA9CA12KDM4EALDH1A1
SCHEMBL12841581 0.87 CA9 (0.50) CA1CA9CA12KDM4EALDH1A1
SCHEMBL29947213 0.87 CA12 (0.64) CA1CA9CA12KDM4EALDH1A1
SCHEMBL14725053 0.87 CA12 (0.64) CA1CA9CA12KDM4EALDH1A1
SCHEMBL29758957 0.87 CA12 (0.64) CA1CA9CA12KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049078-A1 DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2026-02-19 US disclosed
EP-4558494-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.p.A. (IT) 2025-05-28 EP disclosed
US-20250059139-A1 COMPOUNDS FOR TREATMENT OF CANCER THE JOHNS HOPKINS UNIVERSITY 2025-02-20 US disclosed
EP-4452946-A2 COMPOUNDS FOR TREATMENT OF CANCER The Johns Hopkins University (US) 2024-10-30 EP disclosed
EP-3152190-B1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS HARO PHARMACEUTICAL INC (US) 2024-07-31 EP disclosed
WO-2024017897-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.P.A. (IT) 2024-01-25 WO disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 US disclosed
WO-2023122612-A2 COMPOUNDS FOR TREATMENT OF CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 CA1 2006/4885CA9 3614/4885CA12 3023/4885
US-20260049078-A1 DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS HDAC3, HDAC1, HDAC6 CA1 200/4885CA9 253/4885CA12 460/4885
US-20250059139-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, ACP3, TP53 CA1 1895/4885CA9 152/4885CA12 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.